Dedicated to

Better Health

World leading manufacturer of recombinant human albumin

We're on the Move! Starting from May 28th, 2024, you will find all the details of our Recombumin® portfolio and Albumedix' services at our new online home, sartorius.com
  • Contact
  • Albumin
    • Why albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® Products
    • Compliance Services
    • Innovation Services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • COVID-19
  • About
    • About Albumedix
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Albumedix
  • Albumedix
  • CSR
  • FAQ
  • Contact

A science-driven, albumin focused biotechnology company

Too many people battle with diseases that keep them from living a full life. Healthcare professionals work hard every day to provide these people with better therapies. Together with partners, Albumedix utilize its albumin-based drug enhancing products and technologies to enable the development of more effective treatments.

With more than 30 years of experience, we are proud to be recognized as the world leader in recombinant human albumin products and technologies.

As the highest quality recombinant hu­man albumin products ever developed, Albumedix enables the effective formulation of otherwise hard-to-stabilize drugs, cell therapies, and vaccines.

Our albumin-based tech­nologies offer new ways of optimizing drug dosing and enhancing therapeutic performance by increasing the half-life, payload capacity, and tissue specific delivery of active pharmaceutical agents. This results in simpler treatment regi­mens, better performance, and, ultimate­ly, improved patient outcomes.

Albumedix is headquartered in Nottingham, UK, with both research and large-scale manufacturing facilities. We are all committed to improving patient quality of life and are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

Learn more about our products and technologies and how they are already making a difference in the world today (pipeline).

To stay connected with us and take part in our dedication to better health, follow us on LinkedIn.

 

 

 

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Why albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® Products
    • Compliance Services
    • Innovation Services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • COVID-19
  • About
    • About Albumedix
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more